CC
REGN icon

Claybrook Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Claybrook Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-861
Closed -$481K – 221
2021
Q2 		$481K Buy
+861
New +$436K 0.16% 111
2019
Q1 		– Sell
-142
Closed -$53K – 550
2018
Q4 		$53K Buy
+142
New +$52K 0.01% 259

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Claybrook Capital's REGN Position: Q3 2021 in Review

Claybrook Capital sold out of Regeneron Pharmaceuticals (REGN) in Q3 2021, closing a stake of 861 shares — an estimated $481K sold.

Claybrook Capital first reported a position in REGN in Q4 2018 and held it in 2 quarters. The position peaked at $481K in Q2 2021. 1,019 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

  • Claybrook Capital reported no remaining Regeneron Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Claybrook Capital sold 861 Regeneron Pharmaceuticals shares in Q3 2021, an estimated $481K.
  • Claybrook Capital first reported a position in Regeneron Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Claybrook Capital's Regeneron Pharmaceuticals position peaked at $481K in Q2 2021.
  • 1,019 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on Claybrook Capital's 13F filing for Q3 2021, filed 15 Nov 2021.